Last reviewed · How we verify
Freeze-dried Human Protein C Concentrate
Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting.
Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting. Used for Prevention of deep vein thrombosis and pulmonary embolism in patients with hereditary protein C deficiency.
At a glance
| Generic name | Freeze-dried Human Protein C Concentrate |
|---|---|
| Sponsor | Takeda |
| Drug class | Coagulation factor replacement |
| Target | Protein C |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Freeze-dried Human Protein C Concentrate is a replacement therapy for patients with hereditary protein C deficiency, which increases the risk of blood clots. By replacing the deficient protein C, it helps to regulate blood clotting and prevent excessive clotting.
Approved indications
- Prevention of deep vein thrombosis and pulmonary embolism in patients with hereditary protein C deficiency
Common side effects
- Hemorrhage
- Thrombocytopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Freeze-dried Human Protein C Concentrate CI brief — competitive landscape report
- Freeze-dried Human Protein C Concentrate updates RSS · CI watch RSS
- Takeda portfolio CI